Advancing a Pipeline of Targeted Precision Oncology Therapeutics
Kinase inhibition is a proven approach to fighting cancer, and for nearly two decades has addressed an increasing number of oncology indications. At Kinnate, we employ a consistent, systematic approach to identify kinases that drive difficult-to-treat, genomically defined diseases.
Through this approach, we aim to develop kinase inhibitor product candidates with therapeutic windows that provide durable and meaningful clinical responses to benefit patients in three patient populations:
- those with cancers that harbor known oncogenic drivers with no currently available targeted therapies;
- those with genomically well-characterized tumors that have intrinsic resistance to currently available treatments; and
- those whose tumors have acquired resistance over the course of therapy to currently available treatments.
By focusing on these three well-characterized patient populations, we believe that we will have a more efficient development path with a greater likelihood of success. Due to advancements in genomic profiling and relationships with our collaborating precision medicine cancer centers and leading research institutions, we have established and continue to develop a deep expertise and understanding of specific oncogenic drivers.
Kinnate has a broad pipeline with multiple programs targeting validated oncogenic drivers. Our lead program, KIN-2787, is currently being studied in a phase 1 clinical trial and is focused on cancers that are driven by specific oncogenic alterations in the BRAF kinase gene not served by approved therapies. Our FGFR program (KIN-3248), which is also currently being studied in a phase 1 clinical trial, targets a significant unmet need of resistance to current FGFR inhibitors. We are also advancing a number of other small molecule development programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. To help progress these programs, Kinnate is working with leaders at experienced precision medicine cancer centers including Massachusetts General Hospital Cancer Center and the UC San Diego Moores Cancer Center.
A Focused Pipeline Portfolio
We have developed a proprietary kinase inhibitor portfolio of small molecule candidates targeting genomically defined cancers.
RAF / KIN-2787 Monotherapy
RAF / KIN-2787 Combination
FGFR2/3 / KIN-3248
CDK12 / KIN004
Phase 1 Placeholder
Phase 2 Placeholder
Phase 3 Placeholder
“Kinnate’s targeted approach will fill a significant unmet need and potentially bring better precision therapies to cancer patients. As an SAB member, I look forward to working closely with the Kinnate team to advance its pipeline of innovative kinase inhibitors.”
– Ezra Cohen, MD, FRCPSC, FASCO, Kinnate SAB Member